ABSTRACT

Quality by Design (QbD) is defined by the ICH Q8(R2) guideline as "a systematic approach to development that starts with predefined objectives and emphasizes product and process understanding and Process control, based on sound science and Quality Risk Management." Pharmaceutical QbD is an organized method of development that starts with predetermined goals and places a strong emphasis on understanding and controlling processes and products using good science and quality risk management. Eliminate batch errors, avoid problems with legal compliance, Reliable, agile, and flexible system Increase efficiency in production, reduce costs, project rejections, and waste Establish a foundation of scientific knowledge for every product. Analytical Quality by Design (AQbD) or analytical applications of the QbD principle are also possible. It allows movement within the range of the Method Operable Design (MODR) for analytical procedure. The analytical technique developed using AQbD in the method development process minimizes the amount of Out-of-Trend (OOT) and Out-of- Specification (OOS) discoveries, unlike current methods, because of the method's robustness within the region. The primary obstacle to the adoption of quality by design is a lack of understanding about the pharmaceutical process, despite the fact that QbD is a critical component of the current approach to pharmaceutical quality. Keywords: Quality by Design, Analytical Quality by Design (AQbD), Out-of-Trend, Out-of-Specification
Publication date: 01/06/2025

https://ijbpas.com/pdf/2025/June/MS_IJBPAS_2025_9142.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.6.9142